Low- and middle-income countries will be able to purchase an effective preventative at a reduced price. The arrangements may help stem the epidemic 40 years after it began.
Category: Gilead Sciences Inc
-
Promise of Victory Over H.I.V. Fades as U.S. Withdraws Support
A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much of the funding for that effort is gone.
-
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
Many middle-income countries are left out of the deal, widening a gulf in access to critical medicines.
-
Gilead Shot Provides Total Protection From HIV in Trial of Young African Women
An injection given just twice a year could herald a breakthrough in protecting the population that has the highest infection rates.
-
U.S. Lags Behind Other Countries in Hepatitis-C Cures
Despite an arsenal of drugs, many Americans are still unaware of their infections until it’s too late. A Biden initiative languishes without Congressional approval.
-
How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy
Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.
-
U.S. Loses Key Case on Rights to H.I.V.-Prevention Drugs
In an unusual court trial, a federal jury sided with the drug maker Gilead Sciences in a dispute over who came up with the idea of using a daily pill to prevent H.I.V.